Actively Recruiting
Evaluation of HER2DX Assay on Treatment Decisions in Patients With Early Stage HER2+ Breast Cancer: the HER2BREASTDX
Led by European Institute of Oncology · Updated on 2026-02-11
60
Participants Needed
1
Research Sites
157 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To prospectively evaluate the impact of HER2DX on the decision-making processes of the treating physicians and especially among the routine multidisciplinary tumour board, in defining type and setting of systemic therapy administration in patients with stage I-III HER2+ BC, and the degree of clinician's confidence in the treatment recommendation.
CONDITIONS
Official Title
Evaluation of HER2DX Assay on Treatment Decisions in Patients With Early Stage HER2+ Breast Cancer: the HER2BREASTDX
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients 18 years of age or older
- Histologically confirmed HER2-positive breast cancer
- Stage I-III breast cancer without distant metastases
- Candidates for neoadjuvant or adjuvant therapy and locoregional treatment (surgery with or without radiotherapy)
- Signed written informed consent for study procedures
You will not qualify if you...
- HER2-negative breast cancer
- Stage IV breast cancer
- Unable or unwilling to provide informed consent due to incapacity or unwillingness to participate
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Istituto Europeo di Oncologia
Milan, Italy, Italy
Actively Recruiting
Research Team
P
Paola Zagami
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here